ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla cant – Endpoints News

If a record IPO wasn’t enough to put RemeGen on the map, perhaps a deal with Seagen — sporting $200 million in cash — might.
At the center of the licensing pact is disitamab vedotin, an anti-HER2 an… [+611 chars]